USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medimop Medical Projects Ltd.

USPTO PatentsView assignee record — 45 granted patents across 15 technology areas, active 2015–2018. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).

45
Total patents granted
15
CPC technology areas
9.9
Avg claims per patent
-100%
5-year filing velocity

The verdict

Medimop holds 45 US patents across 15 technology areas — rank #7,295 of 50,000 tracked assignees.

#7,295
of 50,000 US assignees by volume
Top 57%
by Innovation Score (32.9/100)
9.9
avg claims per patent
-100%
filing velocity, last 5 yrs

Portfolio overview

MEDIMOP MEDICAL PROJECTS LTD. has been granted 45 US utility patents between 2015 and 2018, placing MEDIMOP MEDICAL PROJECTS LTD. at rank #7,295 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 9.9 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a Foreign Corporation, MEDIMOP MEDICAL PROJECTS LTD. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 32.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 45 in the 2015–2019 window — a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. MEDIMOP MEDICAL PROJECTS LTD.'s 9.9 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark MEDIMOP MEDICAL PROJECTS LTD. against peers pursuing similar technology classes.

How does MEDIMOP compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows MEDIMOP holds 45 patents — placing it at rank #7,295 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

MEDIMOP's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

33 Top 57% higher than 43% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2018

681012141618 2015201620172018 7
USPTO utility patent grants by year · 2015–2018

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
MEDIMOP MEDICAL PROJECTS LTD. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 10 22.2%
2016 16 35.6%
2017 12 26.7%
2018 7 15.6%

Which technologies does MEDIMOP MEDICAL PROJECTS LTD. patent most?

Top 15 of 15 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Simple
Velocity Declining

Where it ranks

Overall rank by patents

#7,295

Across all tracked assignees

Innovation Score

32.9 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does MEDIMOP MEDICAL PROJECTS LTD. hold?
MEDIMOP MEDICAL PROJECTS LTD. holds 45 US granted patents filed between 2015 and 2018, spanning 15 technology areas.
What is MEDIMOP MEDICAL PROJECTS LTD.'s Innovation Score?
MEDIMOP MEDICAL PROJECTS LTD. has an Innovation Score of 32.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does MEDIMOP MEDICAL PROJECTS LTD. focus on?
MEDIMOP MEDICAL PROJECTS LTD.'s top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 24 patents. The company has filed patents in 15 CPC subclasses total.
Is MEDIMOP MEDICAL PROJECTS LTD.'s patent filing rate increasing or decreasing?
MEDIMOP MEDICAL PROJECTS LTD.'s recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for MEDIMOP MEDICAL PROJECTS LTD.'s patents?
MEDIMOP MEDICAL PROJECTS LTD.'s patents average 9.9 claims each. This is relatively simple claim structure, typical for focused inventions.
How is the MEDIMOP MEDICAL PROJECTS LTD. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How to use this portfolio

Medimop's 45 grants land it in the top 57% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Medimop ranks #7,295 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61M — see who else leads that technology area. A61M leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov